

EXAMINER: Abdel A. Mohamed

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

* If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 39766-0037 C3C1	APPLICATION NO. 10/782,281 To be Assigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Louis E. BURTON, et al.	
(USE SEVERAL SHEETS IF NECESSARY)		FILING DATE 2/18/04 Herewith	GROUP 1653 To be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	Ref. No.	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
<i>AM</i>	1 *	4,407,744	04.10.83	Young, D.			
	2 *	4,565,785	21.01.86	Gilbert, et al.			
	3 *	4,673,641	16.06.87	George, et al.			
	4 *	4,710,473	01.12.87	Morris			
	5 *	4,738,921	19.04.88	Belagaje, et al.			
	6 *	4,795,706	03.01.89	Hsiung, et al.			
	7 *	5,082,774	21.01.92	Heinrich, et al.			
	8 *	5,169,762	08.12.92	Gray, A.M., et al.			
	9 *	5,210,185	11.05.93	Delli Valle, et al.			
	10 *	5,235,043	10.08.93	Collins, et al.			
	11 *	5,272,063	21.12.93	Chan, H., et al.			
	12 *	5,288,622	22.02.94	Gray, et al.			
	13 *	5,364,769	15.11.94	Rosenthal, A.			
	14 *	5,389,529	14.02.95	Panayotatos, et al.			
	15 *	5,438,121	01.08.95	Barde, et al.			
	16 *	5,453,361	26.09.95	Yancopoulos, G., et al.			
	17 *	5,488,099	30.01.96	Persson, et al.			
	18 *	5,512,661	30.04.96	Shooter, E.M., et al.			
	19 *	5,606,031	25.02.97	Lile, J., et al.			
	20 *	5,639,664	17.06.97	Iwane, M. et al.			
	21 *	5,702,906	30.12.97	Rosenthal, A.			
	22 *	5,705,617	06.01.98	Persson, H., et al.			
	23 *	5,728,803	17.03.98	Urfer, R., et al.			
	24 *	5,733,875	31.03.98	Martin			
	25 *	5,798,448	25.08.98	Caras, I.W., et al.			
<i>AM</i>	26 *	5,830,858	03.11.98	Rosenthal, A.			

EXAMINER:

Abdel A. Mohamed

DATE CONSIDERED:

7/12/09

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 39766-0037 C3C1	APPLICATION NO. 16/782,261 To be Assigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Louis E. BURTON, et al.	
(USE SEVERAL SHEETS IF NECESSARY)		FILING DATE Herewith 2/18/04	GROUP To be Assigned 1653

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	Ref. No.	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
<i>Am</i>	27 *	5,843,914	01.12.98	Johnson, Jr., E., et al.	1	1	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	Ref. No.	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
<i>Am</i>	28 *	685,490	06.12.95	EPO			
	29 *	450,386 A2	09.10.91	EPO			YES NO
	30 *	414,151	15.03.95	EPO			
	31 *	121,338	10.10.84	EPO			
	32 *	WO 92/05254	02.04.92	PCT			
	33 *	WO 92/22665	23.12.92	PCT			
	34 *	WO 95/16701	22.06.95	PCT			
	35 *	WO 95/30686	16.11.95	PCT			
<i>Am</i>	36 *	WO 95/33829	14.12.95	PCT			

EXAMINER INITIAL	Ref. No.	OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.)
<i>Am</i>	37 *	Angeletti, "Nerve Growth Factor from Cobra Venom" <u>Proc. Natl. Acad. Sci. USA</u> 65(3):668-674 (1970)
	38 *	Angeletti, et al. "Nerve Growth Factor From Mouse Submaxillary Gland: Amino Acid Sequence" <u>Proc. Natl. Acad. Sci. USA</u> 68(10):2417-2420 (1971)
	39 *	Angeletti, et al. "Purification Characterization, and Partial Amino Acid Sequence" <u>Biochem</u> 15:26-34 (1976)
	40 *	Barnett, et al., "Physicochemical Characterization of Recombinant Human Nerve Growth Factor Produced in Insect Cells with a Baculovirus Vector" <u>J. of Neurochemistry</u> 57(3):1052-1061 (1991)
	41 *	Belew, et al., "Chick Embryo Nerve Growth Factor" <u>Exp. Cell Res.</u> 167:550-558 (1986)
	42 *	Berkmeier, et al., "Neurotrophin-5: A Novel Neurotrophic Factor That Activates trk and trkB" <u>Neuron</u> 7:857-866 (November 1991)
	43 *	Bigon, et al., "Large Scale Purification and Immunological Characterization of Human Placental Nerve Growth" <u>Neurochemical Research</u> 15(12):1197-1202 (1990)
	44 *	Bocchini, et al., "The Nerve Growth Factor: Purification as a 30,000-Molecular-Weight Protein" <u>Proc. Natl. Acad. Sci. USA</u> 64:787-794 (1969)
	45 *	Bradshaw, "Nerve Growth Factor" <u>Ann. Rev. Biochem.</u> 47:191-216 (1978)
	46 *	Bruce, et al., "Production and Characterization of Biologically Active Recombinant Human Nerve Growth Factor" <u>Neurobiology</u> 10:89-94 (1988)
	47 *	Buj-Bello, et al., "GDNF Is an Age-Specific Survival Factor for Sensory and Autonomic Neurons" <u>Neuron</u> 15:821-828 (1995)
	48 *	Burton, et al., "Activity and Biospecificity of Proteolyzed Forms and Dimeric Combinations of Recombinant Human and Murine Nerve Growth Factor" <u>J. Neurochem.</u> 59(5):1937-1945 (1992)
<i>Am</i>	49 *	Callegaro, L., et al. "Biological and Immunochemical Properties of Recombinant Human NGF" <u>Trophic Factors and the Nervous System</u> , L. A. Horrocks, et al., New York: Raven Press, Ltd. pps. 75-82 (1990)

EXAMINER: *Abdel A. Mohamed*DATE CONSIDERED: *7/12/04*

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 39766-0037 C3C1	APPLICATION NO. 10/982,261 To be Assigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)		APPLICANT Louis E. BURTON, et al.	
		FILING DATE 2/18/04 Herewith	GROUP 1653 To be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	Ref. No.	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
<i>AM</i>	50 *	Chapman, et al., "The Isolation and Characterization of Nerve Growth Factor from the Prostate Gland of the Guinea Pig" <u>European Journal of Biochemistry</u> 115:347-351 (1981)					
<i>↑</i>	51 *	De Young, et al., "RHNGF Slow Unfolding is not Due to Proline Isomerization: Possibility of a Cystine Knot Loop-Threading Mechanism" <u>Protein Sci.</u> 5(8):1554-1566 (1996)					
	52 *	Dicou, et al., "Synthesis of Chimeric Mouse β -Nerve Growth Factor Precursor and Human β -Nerve Growth Factor in Escherichia coli: Immunological Properties" <u>Journal of Neuroscience Research</u> 22:13-19 (1989)					
	53 *	Edwards, et al., "Processing and Secretion of Nerve Growth Factor: Expression in Mammalian Cells with a Vaccinia Virus Vector" <u>Molecular & Cellular Biology</u> 8(6):2456-2464 (1988)					
	54 *	Emfors, et al., "Molecular Cloning and Neurotrophic Activities of a Protein With Structural Similarities to Nerve Growth Factor: Developmental and Topographical Expression in the Brain" <u>Proc. Natl. Acad. Sci. USA</u> 87:5454-5458 (July 1990)					
	55 *	Goldstein, et al., "ISOLATION OF HUMAN NERVE GROWTH FACTOR FROM PLACENTAL TISSUE" <u>Neurochemical Research</u> 3:175-183 (1978)					
	56 *	Hallbook, et al., "Evolutionary Studies of the Nerve Growth Factor Family Reveal a Novel Member Abundantly Expressed in Xenopus Ovary" <u>Neuron</u> 6:845-858 (May 1991)					
	57 *	Heinrich, et al., "Nerve Growth Factor (NGF) is Present in Human Placenta and Semen, But Undetectable in Normal and Paget's Disease Blood: Measurements with an Anti-Mouse NGF Enzyme Immunoassay Using a Recombinant Human NGF Reference" <u>Biochemical and Biophysical Research Communications</u> 155(1):482-486.					
	58 *	Henerson, et al., "GDNF: A Potent Survival Factor for Motoneurons Present in Peripheral Nerve and Muscle" <u>Science</u> 266:1062-1064 (1994).					
	59 *	Hohn, et al., "Identification and Characterization of a Novel Member of the Nerve Growth Factor/Brain-derived Neurotrophic Factor Family" <u>Nature</u> 344:339-341 (March 22, 1990)					
	60 *	Ip, et al., "Mammalian Neurotrophin-4: Structure, Chromosomal Localization, Tissue Distribution, and Receptor Specificity" <u>Proc. Natl. Acad. Sci. USA</u> 89:3060-3064 (April 1992)					
	61 *	Iwai, et al., "Deoxyribonucleic acids and Related Compounds. XXII. Synthesis of Genes for Human Nerve Growth Factor and Its Fused Protein" <u>Chem. Pharm. Bull.</u> 34(11):4724-4730 (1986)					
	62 *	Jones, et al., "Molecular Cloning of a Human Gene that is a Member of the Nerve Growth Factor Family" <u>Proc. Natl. Acad. Sci. USA</u> 87:8060-8064 (1990)					
	63 *	Jongstra-Bilen, et al., "The in vitro processing of the NGF Precursors by the γ -subunit of the 7s NGF complex" <u>Molecular Brain Research</u> 5:159-169 (1989)					
	64 *	Kahle, et al., "The Amino Terminus of Nerve Growth Factor is Involved in the Interaction with the Receptor Tyrosine Kinase p140 ^{trkA} " <u>Journal of Biological Chemistry</u> 267(32):22707-22710 (November 15, 1991)					
	65 *	Kaisho, et al., "Cloning and expression of a cDNA encoding an oval human neurotrophic factor" <u>FEBS Letters</u> 266(1,2):187-191 (June 1990)					
	66 *	Kanaya, et al., "Synthesis and Secretion of Human Nerve Growth Factor by Saccharomyces Cerevisiae" <u>Gene</u> 83:65-74 (1989)					
	67 *	Kotzbauer, et al., "Neurturin, a relative of glial-cell-line-derived neurotrophic factor" <u>Nature</u> 384:467-470 (1996)					
	68 *	Leibrock, et al., "Molecular Cloning and Expression of Brain-Derived Neurotrophic Factor" <u>Nature</u> 341:149-152 (September 14, 1989)					
	69 *	Lin, et al., "GDNF: A Glial Cell Line-Derived Neurotrophic Factor for Midbrain Dopaminergic Neurons" <u>Science</u> 280:1130-1132 (1993)					
	70 *	Maisano, et al., "SYNTHESIS OF NEW HYDROPHOBIC ADSORBENTS BASED ON HOMOLOGOUS SERIES OF UNCHARGED ALKYL SULPHIDE AGAROSE DERIVATIVES" <u>Journal of Chromatography</u> 321:305-317 (1985)					
	71 *	Maisonpierre, et al., "Neurotrophin-3: A Neurotrophic Factor Related to NGF and BDNF" <u>Science</u> 247:1448-1451 (March 23, 1990)					
	72 *	Mobley, et al., "Characterization of Isolation of Proteolytically Modified Nerve Growth Factor" <u>Biochemistry</u> 15:5543-5552 (1978)					
	73 *	Norrgren, et al., "Release of Nerve Growth Factor by Human Glial Cells in Culture" <u>Experimental Cell Research</u> 130:31-39 (1980)					
<i>AM</i>	74 *	Pantazis, "Nerve Growth Factor Synthesized by Mouse Fibroblast Cells in Culture: Absence of α and γ Subunits" <u>Biochemistry</u> 22:4264-4271 (1983)					

EXAMINER: *Abdel A. Mohamed*DATE CONSIDERED: *7/12/04*

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 39766-0037 C3C1	APPLICATION NO. 10/782,261 To be Assigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (USE SEVERAL SHEETS IF NECESSARY)	APPLICANT Louis E. BURTON, et al.	
	FILING DATE 2/18/09 Herewith	GROUP 1653 To be Assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	Ref. No.	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
<i>AM</i>	75 *	Rosenthal, et al., "Primary Structure and Biological Activity of a Novel Human Neurotrophic Factor" <u>Neuron</u> 4: 767-773 (May 1990)					
	76 *	Rusenko, et al., "Interaction of [¹²⁵ I] Nerve Growth Factor with Acidic Proteins" <u>Neurochemical Research</u> 6(3): 287-300 (1981)					
	77 *	Saboori, et al., "Nerve Growth Factor: Biosynthetic Products of the Mouse Salivary Glands. Characterization of Stable High Molecular Weight and 32,000-Dalton Nerve Growth Factors" <u>Biochemistry</u> 25: 5565-5571 (1986)					
	78 *	Schmelzer, et al. "Biochemical Characterization of Recombinant Human Nerve Growth Factor" <u>Journal of Neurochemistry</u> 59(5): 1675-1683 (1992)					
	79 *	Scott, et al., "Isolation and nucleotide sequence of a cDNA encoding the precursor of mouse nerve growth factor" <u>Nature</u> 302: 538-540 (1983)					
	80 *	Shih, et al., "Mutagenesis Identifies Amino-terminal Residues of Nerve Growth Factor Necessary for Trk Receptor Binding and Biological Activity" <u>Journal of Biological Chemistry</u> 269: 27679-27686 (1994)					
	81 *	Suda, et al., "Nerve Growth Factor in Mouse and Rat Serum: Correlation Between Bioassay and Radioimmunoassay Determination" <u>Proc. Natl. Acad. Sci. USA</u> 75(8): 4042-4046 (1978)					
	82 *	Ulrich, et al., "Human β -Nerve Growth Factor Gene Sequence Highly Homologous to That of Mouse" <u>Nature</u> 303: 821-825 (June 1983)					
	83 *	Ulrich, et al., "Sequence Homology of Human and Mouse B-NGF Subunit Genes" <u>Symposium on Quant. Biol.</u> 48: 435-442 (1983)					
	84 *	Urfer, et al., "The Binding Epitopes of Neurotrophin-3 to its Receptors trkC and gp75 and the Design of a Multifunctional Human Neurotrophin" <u>The EMBO Journal</u> 13(24): 5896-5909 (1994)					
	85 *	Varon, et al., "The Isolation of the Mouse Nerve Growth Factor Protein in a High Molecular Weight Form" <u>Biochemistry</u> 6(7): 2202-2209 (1967)					
<i>AM</i>	86 *	Walker, et al., "Human Nerve Growth Factor: Lack of Immunocross-activity with Mouse Nerve Growth Factor" <u>Life Sciences</u> 26: 195-200 (1980)					

S:\DOCS\JMJM-7922.DOC
060502

EXAMINER: <i>Aldeed A. Mohamed</i>	DATE CONSIDERED: <i>7/10/09</i>
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	
*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).	